Molecular Quality Controls Market

Global Molecular Quality Controls Market Size (2023 to 2028)

The global market size for molecular quality controls is forecasted to be growing at a CAGR of 11.2% from 2023 to 2028 and be worth USD 340.1 million by 2028 from USD 200.04 million in 2023.

Molecular quality control refers to the testing and reporting any irregularities in diagnostic products that may impact the product's approval for use in laboratories. Molecular laboratories employ stringent quality control processes to monitor testing for systematic and random errors and detect immediate data shifts and anomalies in long-term trends. Early detection of probable anomalies is essential for laboratories since it can respond quickly and avoid destroying patient data.

Impact of COVID-19 on the global molecular quality controls market:

The emergence of the novel coronavirus outbreak has caused global disruptions never seen before. While this disruptive force has wreaked havoc on many industries, the molecular quality controls market has the potential to thrive during the pandemic, as clinical laboratories and diagnostic manufacturers scramble to meet the growing demand for testing solutions, which are seen as essential to COVID-19 disease management. To that aim, ZeptoMetrix has announced the inclusion of new molecular quality control to its extensive array of Infectious Disease NATtrolTM Quality Controls. The rising demand for molecular quality control is projected to fuel COVID-19 testing significantly if clinical testing extends beyond symptomatic patients. Because the disease is expected to last longer, the FDA has granted an emergency use authorization (EUA) for molecular diagnostic tests, which are more accurate and have a shorter development period than serological tests. Hence the market has had positive growth during the pandemic.

MARKET DRIVERS:

The global molecular quality controls market is expected to be propelled forward by the increasing adoption of third-party quality controls, the growing number of accredited clinical laboratories, the rising demand for external quality assessment support, increasing government funding to support genomics projects, increasing demand for personalized medicines, declining sequencing costs, and the increasing prevalence of infectious diseases, cancer, and genetic diseases. One of the other primary factors driving the growth of the molecular quality control market is the rising frequency of genetic abnormalities such as Down syndrome. The testing method is frequently used to discover genetic diseases since it aids in interpreting data. Various governmental and commercial institutions are expanding their investments in developing new interventions and therapies that will benefit the market.

The market growth is also boosted by players' focus on new launches and alliances to increase their product portfolio and regional presence. Furthermore, the rising need for effective medications, rising healthcare spending, the prevalence of HIV infection, population expansion, changes in lifestyle, and increasing demand for external quality assessment help are other favorable factors influencing the molecular quality controls market. The increase in demand for multi-analyte controllers provides profitable opportunities for market players in the forecast period. In addition, significant government and private sector investments would drive the growth of the molecular quality controls market over the forecast period.

MARKET RESTRAINTS:

For clinical laboratories that perform modest volumes of diagnostic tests, the expense of implementing QC procedures is prohibitively expensive. This, combined with funding constraints in many hospitals and laboratories in developed and emerging economies, is projected to lead to a decreased adoption of quality-control techniques. An unfavorable reimbursement environment for molecular diagnostic tests, high costs associated with the quality control procedure, and budget restraints of end-users such as hospitals and clinical laboratories are expected to hinder the growth of the molecular quality controls market. In the forecast period, the molecular quality controls market is expected to be challenged by a lack of obligatory requirements for clinical laboratory certification and complex regulatory frameworks.

REPORT COVERAGE:

This research report on the global molecular quality controls market has been segmented and sub-segmented based on product, application end-user, and region.

Molecular Quality Controls Market – By Product:

• Independent Controls
• Instrument Specific Controls

Based on the product, the independent control segment is expected to have the most market share of the molecular quality controls market due to their extremely precise, unbiased, and independent assessment of a testing system or technique performance test findings in a short time with the highest sensitivity rate. Furthermore, a sharp increase in the usage of these products among third-party independent quality controls is likely to boost the market, owing to benefits such as a wide range of applications and lower operational costs.

Molecular Quality Controls Market – By Application:

• Infectious Diseases Diagnostics
• Oncology Testing
• Genetic Testing

The infectious disease diagnostics segment accounted for the largest share of the market. The development of advanced assays for infectious diseases, a significant increase in the prevalence of contagious diseases, and rising awareness about the effective use of molecular diagnostic technologies to control the occurrence and spread of infectious diseases contribute to this segment's size.

Molecular Quality Controls Market – By End-User:

• Diagnostic Laboratories
• Hospitals
• IVD Manufacturers & CROs
• Academic and Research Institutes 

The diagnostic Laboratories segment held the most significant share of the molecular quality control market, with the number of accredited diagnostic laboratories expected to expand during the forecast period.

Molecular Quality Controls Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America is likely to dominate the global molecular quality control market throughout the forecast period. The region's market is expected to be fueled by a high adoption rate of modern infrastructure and an increase in the number of diagnostic centers and recognized clinical laboratories. Because of the developed healthcare systems in the United States and Canada, the existence of several major molecular quality control product manufacturers in the region, and easy access to technologically advanced products, North America was the largest regional market for molecular quality controls.

The market in the Asia Pacific, on the other hand, is expected to rise at the fastest CAGR during the forecast period. The Asia Pacific molecular quality controls market is being propelled forward by the presence of emerging economies such as China and India and the region's enormous patient population's strong demand for high-quality and reliable diagnostic tests. Furthermore, with cancer becoming a more common health issue in the APAC region due to aging populations and lifestyle changes, the need for precision oncology has become a significant focus of various authorities in the region, prompting the creation of numerous projects.

Europe was the next largest market in terms of revenue, and this trend is projected to continue during the forecast period. The rise in the number of contract research organizations and the demand for third-party quality control help is driving the growth of the molecular quality controls market.

KEY MARKET PARTICIPANTS:

THERMO FISHER SCIENTIFIC, INC., BIO-RAD LABORATORIES, INC., Abbott, Quidel Corporation, Qnostics, Maine Molecular Controls, Inc., Zeptometrix Corporation, Microbiologics, and Seracare Life Sciences are some of the companies playing a vital role in the global molecular quality controls market profiled in this report.

RECENT HAPPENINGS IN THIS MARKET:

• In 2021, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, will continue to expand diagnostics company partnerships by offering InteliQ products, a line of barcoded, load-and-go quality control tubes that improve workflow efficiency, as well as Bio-Unity Rad's QC data management solutions, which help laboratories improve their analytical performance.
• Based on a recent on-site inspection as part of the CAP's Accreditation Programs, the College of American Pathologists (CAP) has granted accreditation to the Innovative Genomics Institute Clinical Laboratory at UC Berkeley in 2021.